MARKET

DCTH

DCTH

Delcath Systems Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.58
-0.21
-1.64%
Closed 16:00 08/07 EDT
OPEN
12.57
PREV CLOSE
12.79
HIGH
12.76
LOW
12.51
VOLUME
29.65K
TURNOVER
--
52 WEEK HIGH
95.90
52 WEEK LOW
5.15
MARKET CAP
48.99M
P/E (TTM)
-0.1395
1D
5D
1M
3M
1Y
5Y

EPS

DCTH News

More
Delcath Schedules Conference Call to Report 2020 Second Quarter Financial Results
NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that it will host a conference call on August 13, 2
GlobeNewswire · 1d ago
Delcath to Present at Canaccord Genuity 40th Annual Growth Conference
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that John Purpura, interim Chief Executive Officer,
GlobeNewswire · 4d ago
80 Biggest Movers From Friday
Gainers Berkeley Lights, Inc. (NASDAQ: BLI) shares jumped 197.5% to close at $65.45 on Friday after the company priced its 8.1 million share IPO at $22 per share.
Benzinga · 07/20 09:11
Roth Capital Initiates Coverage On Delcath Systems with Buy Rating, Announces Price Target of $20
Roth Capital initiates coverage on Delcath Systems (NASDAQ:DCTH) with a Buy rating and announces Price Target of $20.
Benzinga · 06/04 11:13
Delcath Appoints John Purpura As Interim CEO
Benzinga · 05/26 12:37
Delcath Announces Leadership Transition
Appoints John Purpura as interim Chief Executive Officer. NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced
GlobeNewswire · 05/26 12:30
Delcath Systems CEO Simpson, CFO Keck resign
Delcath Systems (NASDAQ:DCTH) -6.3% after-hours on disclosing that CEO Jennifer Simpson and CFO Barbra Keck have resigned, effective June 1. Executive VP a
seekingalpha · 05/23 02:15
Delcath Systems Say In 8K That CEO, CFO Resigning
https://www.sec.gov/Archives/edgar/data/872912/000156459020026736/dcth-8k_20200518.htm
Benzinga · 05/22 20:21

Industry

Medical Equipment, Supplies & Distribution
+0.52%
Healthcare Equipment & Supplies
+0.49%

Hot Stocks

Symbol
Price
%Change

About DCTH

Delcath Systems, Inc. is a late-stage clinical development company with early commercial activity in Europe focused on cancers of the liver. The Company is a specialty pharmaceutical and medical device company developing its product, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS). The Company's system delivers and filters melphalan hydrochloride, which is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). The Company's focus is on the execution of the clinical development program (CDP) in ocular melanoma liver metastases (mOM), intrahepatic cholangiocarncinoma (ICC), hepatocellular carcinoma (HCC or primary liver) and other cancers that are metastatic to the liver.
More

Webull offers kinds of Delcath Systems, Inc. stock information, including NASDAQ:DCTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DCTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DCTH stock methods without spending real money on the virtual paper trading platform.